Biosensor startup Biolinq said Thursday it has raised $4.75 million from new investors, including the New York-based Juvenile Diabetes Research Foundation, following the results of a clinical study of its experimental biomarker monitoring device.
Founders Jared Tagney and Joshua Windmiller, who met while in grad school at UC San Diego, started the company in 2012 as Electrozyme. The company began focusing on the technology it is currently developing in 2015, Tagney said. It’s seeking to commercialize a nickel-sized patch that’s designed to gauge blood-glucose level and take other measurements when the device is applied to the skin.
The San Diego startup is initially developing the device for patients with diabetes who regularly monitor the level of glucose in their blood. It uses sensors to test fluid in the uppermost layer of the skin. (Xconomy)